We are live on ! Find out more
Ensign Peak Advisors

Ensign Peak Advisors Portfolio holdings

AUM $53.7B
1-Year Est. Return 29.47%
This Fund
S&P 500
This Quarter Est. Return
+11.3%
1 Year Est. Return
+29.47%
3 Year Est. Return
+102.45%
5 Year Est. Return
+139.11%
10 Year Est. Return
AUM
$52.3B
AUM Growth
+$4.34B
Cap. Flow
-$146M
Cap. Flow %
-0.28%
Top 10 Hldgs %
26.12%
Holding
2,277
New
427
Increased
521
Reduced
1,052
Closed
79

Top Buys

Rank Stock Value
1
IS
ironSource Ltd.
IS
+$136M
2
TSLA icon
Tesla
TSLA
+$119M
3
VZ icon
Verizon
VZ
+$109M
4
HD icon
Home Depot
HD
+$101M
5
PFE icon
Pfizer
PFE
+$88M

Top Sells

Rank Stock Value
1
T icon
AT&T
T
+$247M
2
INTC icon
Intel
INTC
+$216M
3
F icon
Ford
F
+$145M
4
GM icon
General Motors
GM
+$143M
5
MU icon
Micron Technology
MU
+$125M

Sector Composition

Rank Sector Weight
1 Technology 25.15%
2 Healthcare 14.97%
3 Financials 14.22%
4 Consumer Discretionary 11.15%
5 Communication Services 8.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BTU icon
1826
Peabody Energy
BTU
$2.83B
$287K ﹤0.01%
+28,500
New +$346K
SRDX
1827
DELISTED
Surmodics
SRDX
$287K ﹤0.01%
5,970
-5,630
-49% -$284K
QURE icon
1828
uniQure
QURE
$2.52B
$286K ﹤0.01%
13,800
JRVR icon
1829
James River Group Holdings
JRVR
$222M
$285K ﹤0.01%
9,900
BLNK icon
1830
Blink Charging
BLNK
$74.1M
$283K ﹤0.01%
+10,680
New +$344K
CRC icon
1831
California Resources
CRC
$4.38B
$283K ﹤0.01%
+6,630
New +$284K
NBHC icon
1832
National Bank Holdings
NBHC
$1.9B
$283K ﹤0.01%
6,440
-4,860
-43% -$212K
ATYR
1833
aTyr Pharma
ATYR
$49M
$283K ﹤0.01%
37,884
ATRA icon
1834
Atara Biotherapeutics
ATRA
$70.5M
$282K ﹤0.01%
717
-2,032
-74% -$855K
NCNO icon
1835
nCino
NCNO
$2.03B
$282K ﹤0.01%
+5,140
New +$334K
RVMD icon
1836
Revolution Medicines
RVMD
$39.1B
$281K ﹤0.01%
+11,150
New +$314K
ALLO icon
1837
Allogene Therapeutics
ALLO
$573M
$280K ﹤0.01%
+18,790
New +$332K
HSII
1838
DELISTED
Heidrick & Struggles
HSII
$280K ﹤0.01%
6,400
KPTI icon
1839
Karyopharm Therapeutics
KPTI
$160M
$279K ﹤0.01%
+2,892
New +$288K
MGNI icon
1840
Magnite
MGNI
$2.82B
$274K ﹤0.01%
+15,630
New +$352K
TBPH icon
1841
Theravance Biopharma
TBPH
$875M
$274K ﹤0.01%
+24,830
New +$216K
WLL
1842
DELISTED
Whiting Petroleum Corporation
WLL
$272K ﹤0.01%
+4,200
New +$275K
KYNB
1843
Kyntra Bio
KYNB
$28.3M
$271K ﹤0.01%
+768
New +$239K
SLQT icon
1844
SelectQuote
SLQT
$132M
$271K ﹤0.01%
29,920
-30,580
-51% -$335K
FCF icon
1845
First Commonwealth Financial
FCF
$2.17B
$269K ﹤0.01%
16,700
HLI icon
1846
Houlihan Lokey
HLI
$10.2B
$269K ﹤0.01%
+2,595
New +$277K
KTOS icon
1847
Kratos Defense & Security Solutions
KTOS
$9.12B
$269K ﹤0.01%
+13,850
New +$292K
VIPS icon
1848
Vipshop
VIPS
$7.13B
$269K ﹤0.01%
32,000
CMPI
1849
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$268K ﹤0.01%
93,334
-26,581
-22% -$99K
PNTG icon
1850
Pennant Group
PNTG
$1.46B
$267K ﹤0.01%
11,582
-12,570
-52% -$291K

Similar funds

Ensign Peak Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, Ensign Peak Advisors held 2,277 positions worth $52.3B, up 9% from $48B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Ensign Peak Advisors's Q4 2021 filing shows 427 new, 521 increased, 1,052 reduced and 79 closed positions. Its largest new stake was ironSource Ltd.: 13,801,563 shares worth $107M. The largest sale was AT&T, an estimated $247M.

By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 24% a quarter earlier, followed by Healthcare and Financials.

  • Ensign Peak Advisors's largest Q4 2021 buy was ironSource Ltd.: 13,801,563 shares worth $107M.
  • Ensign Peak Advisors added most to Tesla in Q4 2021, an estimated $119M increase.
  • Ensign Peak Advisors's biggest Q4 2021 reduction was AT&T, cutting an estimated $247M.
  • Ensign Peak Advisors fully exited Acceleron Pharma in Q4 2021, selling an estimated $21.5M.
  • Ensign Peak Advisors's ten largest holdings make up 26% of its $52.3B portfolio in Q4 2021.
  • Ensign Peak Advisors opened 427 new positions and closed 79 in Q4 2021.
  • Ensign Peak Advisors's portfolio value rose 9% quarter-over-quarter to $52.3B.

Based on Ensign Peak Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.